tbuckley/cabot-search huggingface dataset:
Mandatory preprocedure testing for SARS-CoV-2 for all-comers may not be required for resuming endoscopic services amidst the ongoing COVID-19 pandemic
Authors: Soumya Jagannath, Ashish Agarwal, Deepak Gunjan, Samir Mohindra, Vishal Sharma, Sudipta Dhar Chowdhury, Sanjeev Sachdeva, Vivek A Saraswat, Rakesh Kochhar, Anoop Saraya
Journal: Gut (2020)

We read with interest the study by Hayee et al 1 which reported no COVID-19 infection in healthcare workers (HCWs) or patient after 6208 outpatient GI endoscopic procedures across 18 centres in UK with the use of personal protective equipment (PPE) and infection control policies. Only 3 (0.11%) of 2611 asymptomatic patients had tested positive for SARS-CoV-2 prior to endoscopy. The study is timely and the results are gratifying given the huge perceived risk of cross-infection among HCWs and patients during the ongoing COVID-19 pandemic. The study favours resumption of outpatient diagnostics during COVID-19 recovery phase without mandatory testing. The risk may, however, vary depending on factors such as infection rate in the population and type of the procedure. We are sharing our experience of transmission of COVID-19 following endoscopy across five academic centres in India, which should strengthen their argument.

All patients undergoing endoscopic procedures from 1 April 2020 to 31 May 2020 were included in an observational study. A detailed questionnaire was sent to the participating centres for the following information: (1) endoscopy details: type and indications of GI endoscopy and (2) infection control measures: use of PPE, mandatory policy of preprocedure testing for SARS-CoV-2 and disinfection practices. Outcome measure was new SARS-CoV-2 infection in HCWs or patient. The patients were followed up telephonically …
MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initiating Potential
Authors: Nina Rolf, Angela Tsang, Lorraine Liu, Amanda Lorentzian, Pascal Leclair, Annette Patterson, Philipp Lange, Christopher Maxwell, Chinten J. Lim, Ramon Klein Geltink, Suzanne M. Vercauteren, Gregor S. D. Reid
Journal: Blood (2020)
Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada
Authors: Anuja Chatterjee, Gijs Van de Wetering, Ron Goeree, Anne Marie Desbois, Patricia Manzi, Beenish S Manzoor, Carolyn Owen, Kavita Sail
Journal: Blood (2020)
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Authors: Robert J. Motzer, Romain Banchereau, Habib Hamidi, Thomas Powles, David McDermott, Michael B. Atkins, Bernard Escudier, Li-Fen Liu, Ning Leng, Alexander R. Abbas, Jinzhen Fan, Hartmut Koeppen, Jennifer Lin, Susheela Carroll, Kenji Hashimoto, Sanjeev Mariathasan, Marjorie Green, Darren Tayama, Priti S. Hegde, Christina Schiff, Mahrukh A. Huseni, Brian Rini
Journal: Cancer Cell (2020)
Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity
Authors: Rebecca A. Marsh, Soyoung Kim, Kyle Hebert, Christopher C. Dvorak, Victor Aquino, K. Scott Scott Baker, Deepak Chellapandian, Blachy Davila, Christine Duncan, Michael J. Eckrich, George E. Georges, Timothy S. Olson, Michael A Pulsipher, Shalini Shenoy, Elizabeth Stenger, Mark Vander Lugt, Lolie C. Yu, Andrew Gennery, Mary Eapen
Journal: Blood (2020)
Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France
Authors: Honghao Fang, Harinala Ravonimbola, Nisha C Hazra, Zhou Zhou, Beenish S. Manzoor, Vincent Levy, Loic Ysebaert, Nathanael Kabore, Kavita Sail
Journal: Blood (2020)
Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study
Authors: John E. Godwin, Cesar O. Freytes, Michael Maris, Don A. Stevens, Daanish Hoda, Bassam Mattar, Juan C. Varela, Mohamad Cherry, James Essell, Jay Courtright, Suzanne R. Fanning, Habte A. Yimer, Nikolaus S. Trede, Marina Youssef, James Lymp, Carlos Bachier
Journal: Blood (2020)
Obinutuzumab-Retreatment in Combination with Bendamustine Is Effective for Obinutuzumab Resistant Models <i>in Vitro</i> and <i>In Vivo</i>
Authors: Yoriko Yamashita-Kashima, Natsumi Kawasaki, Keigo Yorozu, Shigeki Yoshiura, Takaaki Fujimura, Mitsue Kurasawa, Naoki Harada, Yasushi Yoshimura
Journal: Blood (2020)
ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Authors: Alan S. Wayne, Gerard Michel, Daniel W. Lee, André Baruchel, Sonali Chaudhury, Patrick A. Brown, Michelle Hermiston, Joerg Krueger, Tong Shen, Kristy Tailford, Behzad Kharabi Masouleh
Journal: Blood (2020)
Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial
Authors: Huiqing Xu, Katherine Chaney, Bryon Johnson, Timothy S. Fenske, Mehdi Hamadani, Boro Dropulic, Dina Schneider, Parameswaran Hari, Nirav N. Shah
Journal: Blood (2020)
CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial
Authors: Gail J. Roboz, Farhad Ravandi, Andrew H Wei, Hervé Dombret, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, C.L. Beach, Alberto Risueño, Daniel Lopes de Menezes, Gert Ossenkoppele
Journal: Blood (2020)
Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study
Authors: Nicholas J. Short, Hagop M. Kantarjian, Farhad Ravandi, Xuelin Huang, Alessandra Ferrajoli, Tapan M. Kadia, Philip A. Thompson, Yesid Alvarado, Nitin Jain, Musa Yilmaz, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Steven M. Kornblau, Marina Konopleva, Guillermo Garcia-Manero, Heather M Schroeder, Monica Kwari, Shilpa Paul, Benjamin Nwakanme, Christopher Loiselle, Rebecca Garris, Susan M. O'Brien, Elias Jabbour
Journal: Blood (2020)
OP0052 Glucosamine sulfate as an osteoarthritis disease modification agent: a confirmatory, long-term, randomised, placebo-controlled, indipendent study
Authors: K Pavelka, J Gatterova, M Olejarova, S Machacek, C Gonzalez, G Giacovelli, LC Rovati
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Recent data showed that glucosamine sulfate is an osteoarthritis disease modifying agent.<sup>1</sup> International guide-lines on clinical development of osteoarthritis drugs recommend to perform at least two independent studies to confirm the drug properties. <h3>Objectives</h3> To confirm the effects of glucosamine sulfate as a disease modifying agent. <h3>Methods</h3> Randomised, double-blind, placebo-controlled, study. 202 patients with knee-osteoarthritis (ACR criteria) were randomised to glucosamine sulfate 1500 mg once-a-day p.o., or placebo for 3 years. The minimum joint space width (JSW) of the narrowest medial compartment of the tibio-femoral joint at 3 years was the study structure primary endpoint, and a secondary endpoint at 1 and 2 years. JSW was measured visually by a 0.1 mm graduated magnifying glass, on standardised weight-bearing antero-posterior radiographs of each knee, in full extension. Symptoms were assessed by both the WOMAC LK 3.0 version and the Lequesne indices. <h3>Results</h3> The two study groups were comparable for demographic and disease characteristics and represented the standard primary-knee-osteoarthritis population. The placebo group presented a progressive joint space narrowing (JSN) at each year of evaluation, while glucosamine sulfate presented no average JSN at any point of evaluation. Results at 3 years are shown in the Table 1 below. Glucosamine sulfate significantly improved symptoms as measured by both the Lequesne: (20–25% vs. &lt;10% with placebo) and the WOMAC (15–20% vs. &lt;2%) indices. No significant differences were seen in the reported adverse events rate, while more patients on the placebo group prematurely left the study, without reaching a statistical significance. <h3>Conclusion</h3> This independent-confirmatory study demonstrated that glucosamine sulfate can be postulated as the first osteoarthritis structure modifying agent. Glucosamine sulfate also improved the disease symptoms in the long-term treatment of the disease, with a safety profile similar to placebo. The action of glucosamine sulfate on both the structure and the symptoms evolution of the disease postulate it as the first osteoarthritis modifying agent. <h3>Reference</h3> Lancet 2001;357:251–6
Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study
Authors: Pietro R Di Ciaccio, David Ritchie, Glen A Kennedy, Sam Milliken, Duncan Purtill, David Gottlieb, Travis Perera, David T Yeung, Stephen R Larsen, Richard Doocey, Matthew Greenwood, Simon Durrant, Anne-Marie Watson, Andrew Butler, Amit Khot, Cameron Curley, Nada Hamad
Journal: Blood (2020)
Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM)
Authors: Erin K. Yeung, Brian R. Primeaux, Sandra B. Horowitz, Brandon R. Shank, Irene Y. Lee, Gregory P. Kaufman, Hans C. Lee, Elisabet E. Manasanch, Krina K. Patel, Robert Z. Orlowski, Donna M. Weber, Sheeba K. Thomas
Journal: Blood (2020)
Abstract 16023: Physicians Feel Competent in Deciding When to Terminate Resuscitation but Have Limited Knowledge on Termination Guidelines and Rely on Unvalidated and Controversial Factors When Abandoning Resuscitation
Authors: Camilla Hansen, Kasper G Lauridsen, Anders S Schmidt, Bo Løfgren
Journal: Circulation (2015)

Introduction: Many resuscitation attempts do not succeed and have to be terminated. Several factors may influence the decision to terminate cardiopulmonary resuscitation (CPR) e.g. medical history, cause of cardiac arrest and anticipated prognosis. The aim of this study was to investigate self-assessed competence in terminating CPR and knowledge of the European Resuscitation Council (ERC) guidelines on termination of resuscitation. In addition, to evaluate single factors resulting in abandonment of CPR. Methods: Questionnaires were distributed to participants before advanced life support training at a university hospital. Participants included nurses and physicians serving as cardiac arrest team leaders and members from emergency, cardiology and intensive care departments. The questionnaire included questions on: 1) self-assessed competence in terminating CPR, 2) knowledge of ERC guidelines on termination of resuscitation, and 3) single factors resulting in abandonment of CPR. Data were collected from October 2014 through May 2015. Results: In total, 215 answers (response rate: 97%; 136 nurses and 79 physicians) were included in the study. Overall, 67% of physicians felt competent in deciding when to terminate CPR. No nurses and two (3%) physicians were able to state the ERC guidelines on when to terminate CPR. Physicians stated the following factors as single causes to terminate CPR: asystole for &gt;20 min and no uncorrected reversible cause of cardiac arrest (75%), witnessed cardiac arrest without bystander CPR within 10 minutes (20%), cardiac standstill during echocardiography (19%), absence of pupillary light reflex during resuscitation (17%), age above 90 years (18%), known cancer (13%) and prolonged cardiac arrest with shockable rhythm (9%). Conclusions: Physicians feel competent in deciding when to terminate CPR. Knowledge on ERC guidelines for termination of resuscitation is limited. Physicians rely on unvalidated and controversial factors as sole ground for abandoning CPR.
Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience
Authors: Justin N. Malinou, Hanan Alkhaldi, Saurabh Dahiya, Olga Goloubeva, Ali Bukhari, Forat Lutfi, Gabriela Sanchez-Petitto, Santanu Samanta, Aaron P. Rapoport, Nancy M. Hardy, Nicolette Minas, Kathleen Ruehle, Natalie Gahres, Linda Ridge, Pranshu Mohindra, Jason Molitoris, Jean A. Yared
Journal: Blood (2020)
Turning Up the Heat on the Pancreatic Tumor Microenvironment by Epigenetic Priming
Authors: Kenneth P. Nephew
Journal: Cancer Research (2020)

Abstract The study by Gonda and colleagues, in this issue of Cancer Research, represents the first combinatorial approach based on epigenetic therapy priming to overcome resistance to immunotherapy in pancreatic cancer. The authors show that treatment with a DNA hypomethylating agent causes profound changes in the pancreatic cancer microenvironment, including increased numbers of tumor-infiltrating T cells, elevated IFN signaling, and immune checkpoint expression, as well as increased antigen presentation in tumor cells. Accordingly, they show that the combination of decitabine plus immune checkpoint blockade effectively restores antitumor immunity and results in a significant survival benefit in a widely accepted mouse model of pancreatic cancer. The study provides evidence for a new therapeutic approach for pancreatic cancer having antitumor efficacy through modulation of the immune suppressive microenvironment, leading to an increased response to immune checkpoint inhibitors. As the incidence of pancreatic cancer continues to increase, new treatment strategies for this devastating disease are urgently needed. Gonda and colleagues provide preclinical proof of concept for a new therapeutic strategy and address an unmet need for this difficult to treat disease. See related article by Gonda et al., p. 4754
Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Jeffrey S. Morris, Rajyalakshmi Luthra, Yusha Liu, Dzifa Y. Duose, Wonyul Lee, Neelima G. Reddy, Justin Windham, Huiqin Chen, Zhimin Tong, Baili Zhang, Wei Wei, Manyam Ganiraju, Bradley M. Broom, Hector A. Alvarez, Alicia Mejia, Omkara Veeranki, Mark J. Routbort, Van K. Morris, Michael J. Overman, David Menter, Riham Katkhuda, Ignacio I. Wistuba, Jennifer S. Davis, Scott Kopetz, Dipen M. Maru
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Consensus molecular subtyping (CMS) of colorectal cancer has potential to reshape the colorectal cancer landscape. We developed and validated an assay that is applicable on formalin-fixed, paraffin-embedded (FFPE) samples of colorectal cancer and implemented the assay in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Experimental Design: We performed an in silico experiment to build an optimal CMS classifier using a training set of 1,329 samples from 12 studies and validation set of 1,329 samples from 14 studies. We constructed an assay on the basis of NanoString CodeSets for the top 472 genes, and performed analyses on paired flash-frozen (FF)/FFPE samples from 175 colorectal cancers to adapt the classifier to FFPE samples using a subset of genes found to be concordant between FF and FFPE, tested the classifier's reproducibility and repeatability, and validated in a CLIA-certified laboratory. We assessed prognostic significance of CMS in 345 patients pooled across three clinical trials. Results: The best classifier was weighted support vector machine with high accuracy across platforms and gene lists (&amp;gt;0.95), and the 472-gene model outperforming existing classifiers. We constructed subsets of 99 and 200 genes with high FF/FFPE concordance, and adapted FFPE-based classifier that had strong classification accuracy (&amp;gt;80%) relative to “gold standard” CMS. The classifier was reproducible to sample type and RNA quality, and demonstrated poor prognosis for CMS1–3 and good prognosis for CMS2 in metastatic colorectal cancer (P &amp;lt; 0.001). Conclusions: We developed and validated a colorectal cancer CMS assay that is ready for use in clinical trials, to assess prognosis in standard-of-care settings and explore as predictor of therapy response.
Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial
Authors: Louise Bouard, Catherine Thieblemont, Krimo Bouabdallah, Thomas Gastinne, Anne Moreau, Sibylle Masse, Rémy Gressin, Lucie Oberic, Alexis Caulier, Emmanuel Gyan, Victoria Cacheux, Olivier Casasnovas, Olivier Hermine, Steven Le Gouill
Journal: Blood (2020)
Contribution of Idasanutlin Exposure to Safety, Pharmacodynamics and Clinical Response of Patients with Acute Myeloid Leukemia Treated with Idasanutlin + Cytarabine in Phase I and III Studies
Authors: Candice Jamois, Doreen Anders, Benjamin M. Beckermann, Magali Genevray, Kirsten Mundt, Claire Petry, Joy Yang, Nastya Kassir, Christophe Schmitt
Journal: Blood (2020)
Co-infections: testing macrolides for added benefit in patients with COVID-19
Authors: Katharina Anna Sterenczak, Israel Barrantes, Thomas Stahnke, Oliver Stachs, Georg Fuellen, Nasrullah Undre
Journal: The Lancet Microbe (2020)

Co-infections: testing macrolides for added benefit in patients with COVID-19Co-infections and pulmonary inflammation are potentially lifethreatening consequences of COVID-19.We believe that for the management of co-infections, macrolide antibiotics are particularly useful.Although azithromycin is actively being pursued, 1 we would also like to suggest josamycin as a worthwhile alternative.Both macrolides are indicated for the treatment of a variety of respiratory infections including pharyngolaryngitis, acute bronchitis, and pneumonia, and the minimum inhibitory concentration of these drugs for the treatment of these infections are rapidly reached in the lungs. 2 With regards to COVID-19, macrolides are well known for their anti-inflammatory and immunomodulatory effects, observed in pulmonary inflammatory disorders such as diffuse panbronchiolitis, asthma, and cystic fibrosis. 3 Recently, we have been particularly interested in josamycin, and we have assembled further evidence (appendix pp 1-7) of its antifibrotic and antiinflammatory effects.On the basis of this evidence, we therefore consider that josamycin could be a good choice for patients with COVID-19, as these patients often develop fibrosisrelated comorbidities and serious inflammatory symptoms.The UK
Analysis of Quality-of-Life (QoL) in Patients Receiving NEPA for Prevention of Chemotherapy-Induced Nausea (CINV) and Vomiting
Authors: Meinolf Karthaus, M O Zahn, B Tschechne, B. Gerber, S Haas, U Schwindel, M Konias, A R Rotmann, J Schilling
Journal: Blood (2020)
Characteristics of Youths Treated With Psychotropic Polypharmacy in the United States, 1999 to 2015
Authors: Chengchen Zhang, O’Mareen Spence, Gloria Reeves, Susan dosReis
Journal: JAMA Pediatrics (2020)

than deaths involving opioids alone.Of the polysubstanceinvolved opioid overdose deaths, stimulants were most commonly involved.Our results are consistent with data from the general adult population, which shows stimulant-involved opioid overdose deaths increasing over the past decade. 3Moreover, our study is consistent with data demonstrating that cocaine is now the substance most commonly coinvolved in opioid overdose deaths. 5 Limitations of this study include potential death misclassification, inaccurate identification of substances, and nonspecific reporting on death certificates causing undercounts of specific drug classes.The CDC WONDER data set is unable to stratify further deaths from psychostimulants other than cocaine, a category that includes methamphetamine and prescribed stimulants.Future studies should further delineate the age-related and geographic differences in polysubstance overdoses over time. 6 These results underscore the evolving heterogeneity of the overdose epidemic among youth.Treatment and harm reduction models for opioid use disorders among youth must recognize and address the co-occurrence of other substance use disorders.
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen
Authors: Patrizia Chiusolo, Stefania Bregante, Sabrina Giammarco, Teresa Lamparelli, Lucia Casarino, Alida Dominietto, Anna Maria Raiola, Elisabetta Metafuni, Carmen Di Grazia, Francesca Gualandi, Federica Sora, Luca Laurenti, Simona Sica, Gianni Barosi, Fabio Guolo, Monica Rossi, Elena Rossi, Alessandro Vannucchi, Alessio Signori, Valerio De Stefano, Andrea Bacigalupo, Emanuele Angelucci
Journal: American Journal of Hematology (2020)

The aim of this retrospective study was to assess the rate of full donor chimerism (F-DC) in patients with myelofibrosis, prepared for an allogeneic stem cell transplant, with one or two alkylating agents. We analyzed 120 patients with myelofibrosis, for whom chimerism data were available on day +30. There were two groups: 42 patients were conditioned with one alkylating agent (ONE-ALK), either thiotepa or busulfan or melphalan, in combination with fludarabine, whereas 78 patients were prepared with two alkylating agents, thiotepa busulfan and fludarabine (TBF). Patients receiving TBF were older (57 vs 52 years), were less frequently splenectomized pre-HSCT (31% vs 59%), had more frequently intermediate-2/high DIPSS scores (90% vs 74%), were grafted more frequently from alternative donors (83% vs 33%) and received more frequently ruxolitinib pre-HSCT (26% vs 7%). The proportion of patients with F-DC on day +30, in the TBF vs the ONE-ALK group, was respectively 87% vs 45% (P < .001). The 5-year cumulative incidence of relapse was 9% in the TBF group, vs 43% for the ONE-ALK group (P < .001). The 5-year actuarial disease-free survival was 63% for TBF and 38% for the ONE-ALK group (P = .004). In conclusion, early full donor chimerism is a prerequisite for long term control of disease in patients with myelofibrosis, undergoing an allogeneic HSCT. The combination of two alkylating agents in the conditioning regimen, provides a higher chance of achieving full donor chimerism on day+30, and thus a higher chance of long term disease free survival.
Role of clonoSEQ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma
Authors: Ajay Nooka, Kyle Bradley, Nisha Joseph, Craig C Hofmeister, Madhav V. Dhodapkar, Larry H. Boise, Sagar Lonial, Shiyong Li, Jonathan L. Kaufman
Journal: Blood (2020)